Schizophrenia
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
MCHR1 expression is decreased in the prefrontal cortex of schizophrenia samples (FDR p< 0.05, CommonMind and PsychEncode combined datasets, N = 901) while PMCH is below the detection threshold.
|
31563948 |
2020 |
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
Our results suggest that MCHR1 may influence schizophrenia susceptibility, in particular among men and patients responding to conventional (nonclozapine) treatment.
|
22081064 |
2012 |
Schizophrenia
|
0.340 |
Biomarker
|
disease |
PSYGENET |
Our results suggest that MCHR1 may influence schizophrenia susceptibility, in particular among men and patients responding to conventional (nonclozapine) treatment.
|
22081064 |
2012 |
Schizophrenia
|
0.340 |
Biomarker
|
disease |
PSYGENET |
Augmentation of disease risk was found for the complex genotype HM74[A,any]+MCHR1[T,any]+MCHR2[C,any] which conferred an OR maximal for the combined diagnostic category of schizophrenia plus bipolar disorder (1.70, p=0.003), carried by 30% of the cases.
|
19502010 |
2009 |
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
Augmentation of disease risk was found for the complex genotype HM74[A,any]+MCHR1[T,any]+MCHR2[C,any] which conferred an OR maximal for the combined diagnostic category of schizophrenia plus bipolar disorder (1.70, p=0.003), carried by 30% of the cases.
|
19502010 |
2009 |
Schizophrenia
|
0.340 |
GeneticVariation
|
disease |
LHGDN |
To our knowledge this is the first study reporting association between GPR24 and BPD and SZ, suggesting that GPR24 variants may confer susceptibility to both disorders.
|
16741940 |
2006 |
Schizophrenia
|
0.340 |
Biomarker
|
disease |
PSYGENET |
To our knowledge this is the first study reporting association between GPR24 and BPD and SZ, suggesting that GPR24 variants may confer susceptibility to both disorders.
|
16741940 |
2006 |
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
To our knowledge this is the first study reporting association between GPR24 and BPD and SZ, suggesting that GPR24 variants may confer susceptibility to both disorders.
|
16741940 |
2006 |
Mental Depression
|
0.330 |
Biomarker
|
disease |
BEFREE |
Animal studies have shown that antagonists of receptor 1 of Melanin-Concentrating Hormone (MCH-R1) elicit antidepressive-like behavior, suggesting that MCH-R1 might be a novel target for the treatment of depression and supports the hypothesis that MCHergic signaling regulates depressive-like behaviors.
|
31376444 |
2019 |
Depressive disorder
|
0.330 |
Biomarker
|
disease |
BEFREE |
Animal studies have shown that antagonists of receptor 1 of Melanin-Concentrating Hormone (MCH-R1) elicit antidepressive-like behavior, suggesting that MCH-R1 might be a novel target for the treatment of depression and supports the hypothesis that MCHergic signaling regulates depressive-like behaviors.
|
31376444 |
2019 |
Mental Depression
|
0.330 |
Biomarker
|
disease |
PSYGENET |
The data indicate that MCH1R participates in the modulation of depression-like behavior through a process that involves the CA1 region of the hippocampus, supporting the possible use of MCH1R antagonists in the treatment of depression.
|
22209364 |
2012 |
Depressive disorder
|
0.330 |
Biomarker
|
disease |
PSYGENET |
The data indicate that MCH1R participates in the modulation of depression-like behavior through a process that involves the CA1 region of the hippocampus, supporting the possible use of MCH1R antagonists in the treatment of depression.
|
22209364 |
2012 |
Mental Depression
|
0.330 |
Biomarker
|
disease |
PSYGENET |
Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression.
|
19182070 |
2009 |
Depressive disorder
|
0.330 |
Biomarker
|
disease |
PSYGENET |
Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression.
|
19182070 |
2009 |
Mood Disorders
|
0.330 |
Biomarker
|
group |
PSYGENET |
We also comment on the utility of small-molecule MCHR1 antagonists for the treatment of obesity and affective disorders compared to existing therapies and provide a critical overview of the potential risks.
|
19418262 |
2009 |
Mood Disorders
|
0.330 |
Biomarker
|
group |
BEFREE |
We also comment on the utility of small-molecule MCHR1 antagonists for the treatment of obesity and affective disorders compared to existing therapies and provide a critical overview of the potential risks.
|
19418262 |
2009 |
Mental Depression
|
0.330 |
Biomarker
|
disease |
PSYGENET |
Taken together, we suggest that antagonism of the MCHR1 receptor may provide a novel approach for the treatment of affective disorders, including depression, with a potentially increased efficacy in women.
|
16934771 |
2007 |
Mental Depression
|
0.330 |
Biomarker
|
disease |
BEFREE |
Taken together, we suggest that antagonism of the MCHR1 receptor may provide a novel approach for the treatment of affective disorders, including depression, with a potentially increased efficacy in women.
|
16934771 |
2007 |
Mental Depression
|
0.330 |
Biomarker
|
disease |
BEFREE |
MCHR1 antagonists might find an additional usage in the treatment of anxiety and depression disorders.
|
17655875 |
2007 |
Mental Depression
|
0.330 |
Biomarker
|
disease |
PSYGENET |
MCHR1 antagonists might find an additional usage in the treatment of anxiety and depression disorders.
|
17655875 |
2007 |
Depressive disorder
|
0.330 |
Biomarker
|
disease |
BEFREE |
Taken together, we suggest that antagonism of the MCHR1 receptor may provide a novel approach for the treatment of affective disorders, including depression, with a potentially increased efficacy in women.
|
16934771 |
2007 |
Depressive disorder
|
0.330 |
Biomarker
|
disease |
BEFREE |
MCHR1 antagonists might find an additional usage in the treatment of anxiety and depression disorders.
|
17655875 |
2007 |
Depressive disorder
|
0.330 |
Biomarker
|
disease |
PSYGENET |
Taken together, we suggest that antagonism of the MCHR1 receptor may provide a novel approach for the treatment of affective disorders, including depression, with a potentially increased efficacy in women.
|
16934771 |
2007 |
Depressive disorder
|
0.330 |
Biomarker
|
disease |
PSYGENET |
MCHR1 antagonists might find an additional usage in the treatment of anxiety and depression disorders.
|
17655875 |
2007 |
Mood Disorders
|
0.330 |
Biomarker
|
group |
PSYGENET |
Taken together, we suggest that antagonism of the MCHR1 receptor may provide a novel approach for the treatment of affective disorders, including depression, with a potentially increased efficacy in women.
|
16934771 |
2007 |